Abstract: The present invention refers to an In vitro method for screening for subjects at risk of developing thoracic aortic aneurysm (TAA) or a disease causing TAA comprising: (a) measuring the expression pattern or level of at least A Disintegrin And Metalloproteinase with Thrombospondin Motifs 1 (ADAMTS1) obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least ADAMTS1 of the subjects to be screened with an already established expression pattern or level, wherein reduced expression of at least ADAMTS1 is indicative of a thoracic aortic aneurysm (TAA).
Type:
Grant
Filed:
December 30, 2016
Date of Patent:
February 2, 2021
Assignees:
Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.), Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid
Inventors:
Juan Miguel Redondo Moya, Nerea Méndez-Barbero, Jorge Oller Pedrosa, Miguel Ramón Campanero García
Abstract: The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
September 22, 2020
Assignee:
UCL Business Ltd
Inventors:
Alex Peter Dyson, Daniel Gooding, Joanne Holland
Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products and compositions comprising acamprosate and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
Type:
Grant
Filed:
June 5, 2014
Date of Patent:
January 1, 2019
Assignee:
Synchroneuron, Inc.
Inventors:
Barry S. Fogel, William D. Kerns, Kei-Lai Fong
Abstract: Highly efficient methods for synthesis of levomethadone hydrochloride or dextromethadone hydrochloride are provided starting from D-alanine, or L-alanine, respectively, with retention of configuration. Methods for treating a subject are provided comprising administering a composition comprising an effective amount of levomethadone hydrochloride having not more than 10 ppm dextromethadone.
Abstract: Compositions and methods including Amodiaquine (AQ) or N-Desethy Amodiaquine (DEAQ) are provided for treating, inhibiting, or preventing cathepsin B dependent pathogens and toxins in a host cell or infected subject. Compositions and methods also include AQ or DEAQ in combination with an antibiotic for more effective clearance of the pathogen and/or toxins.
Type:
Grant
Filed:
October 23, 2015
Date of Patent:
August 7, 2018
Assignee:
Keck Graduate Institute of Applied Life Sciences
Inventors:
Mikhail Martchenko, Leeor Zilbermintz, William Leonardi
Abstract: Bio-regulators from a group of quaternary ammonium moieties modify a gene expression in a plant to induce enhanced growth and robustness. Such bio-regulator may be applied to seeds through coating or encapsulating, to plants through root drenching, spraying and dusting. Bio-regulators may be duel-acting; causing beneficial modification to gene expressions in desirable plants while modifying gene expression in undesirable plants, making them more susceptible to herbicides. Bio-regulators are Ester Compounds, BMIA Compounds or related salts, BMIA Compounds or related salts of those compounds.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
October 11, 2016
Assignee:
KamTec, LLC
Inventors:
Henry Yokoyama, James H. H. Chan, Paul S. Oyama, Loren J. Hov, Christopher Lee Petersen, David Vu, John A. Eastin
Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.
Type:
Grant
Filed:
November 9, 2008
Date of Patent:
February 24, 2015
Assignees:
Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
Inventors:
Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavi
Abstract: Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists.
Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
Abstract: This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity.
Abstract: The present application relates to personal care compositions comprising perfumes and non-sulfur-based perfume raw materials, and methods for making and using the personal care compositions to resist consumer fragrance habituation.
Type:
Application
Filed:
December 13, 2013
Publication date:
June 26, 2014
Applicant:
The Procter & Gamble Company
Inventors:
Jonathan Robert CETTI, Zerlina Guzdar DUBOIS, Virginia Tzung-Hwei HUTCHINS, Michael Wayne KINSEY
Abstract: A compound useful as a plant activator for activating an endogenous defense system of a plant to control disease damage is provided. A compound represented by the formula: (R3)NH—(CH2)4—N(R1)—(CH2)3—NH(R2) (one of R1 and R2 represents a linear C6-18 alkanoyl group or alkenoyl group, the other represents hydrogen atom or a protective group of amino group; and R3 represents hydrogen atom or a protective group of amino group).
Type:
Grant
Filed:
February 23, 2012
Date of Patent:
June 3, 2014
Assignees:
The University of Tokyo, National Institute of Agrobiological Sciences, Riken
Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
Type:
Grant
Filed:
March 22, 2012
Date of Patent:
May 27, 2014
Assignee:
Catabasis Pharmaceuticals, Inc.
Inventors:
Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
Abstract: A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide.
Type:
Grant
Filed:
February 4, 2011
Date of Patent:
May 20, 2014
Assignee:
BASF SE
Inventors:
Bernd Bruchmann, Holger Türk, Daniel Schönfelder, Monika Haberecht, Dietmar Appelhans, Victor Boyko
Abstract: The invention discloses compositions, including nutritional products and dietary supplements, comprising 1,4-dimethylpentylamine, which is a compound that occurs naturally in the geranium plant. The invention also describes methods comprising the administration of 1,4-dimethylpentylamine to mammals. The methods result in stimulation of the central nervous system, improved mood, increased vigor, increased lipolysis, increased energy expenditure, enhanced exercise performance, and/or decreased appetite. These effects influence energy balance and can promote weight loss, improve body composition, and/or promote fitness and well-being.
Abstract: Provided herein are methods of using gaseous nitric oxide and/or at least one nitric oxide source to or decrease sebum production in the skin of a subject.
Abstract: The subject matter disclosed herein relates to agents and methods of treating neoplasms with an agent that is a kinase inhibitor and is also an inducer of autophagy in combination with an agent that is an inhibitor of autophagy.
Abstract: A personal care composition which contains 25-200 ppm of 2-methyl-4-isothiazolin-3-one and at least one hydroquinone radical scavenger, and a method for reducing odor arising in personal care compositions containing 2-methyl-4-isothiazolin-3-one.
Abstract: The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same.
Abstract: The invention provides a method for treating septic shock or endotoxemia, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising formula I, II, III or IV and their salt, ester or solvate thereof.
Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.
Abstract: An extraction method for extracts of Pelargonium citronellum with improved methylhexaneamine content is provided. The method involves separating the oil phase from the aqueous phase; concentrating the aqueous phase; purifying the oil phase; and recombining the resulting material. Additionally, extracts of Pelargonium citronellum prepared by the extraction method are provided. The extracts are useful in compositions, for example as dietary supplements, and for appetite suppression.
Type:
Application
Filed:
March 12, 2013
Publication date:
August 22, 2013
Inventors:
James Akrong, Shawn Shirazi, Jason Peters, John Doherty
Abstract: The invention relates to the use of a composition comprising at least one volatile molecule specific to the estrus of cows in order to improve the reproductive function of a bull. In particular, the composition according to the invention makes it possible to act on the libido of the bull, but also on the production of semen by the bull. Preferably, the composition used comprises at least one molecule from among coumarin, squalene, 6-amino undecane, 2-butanone, 9-octadecenoic acid and 1,2-dichloroethylene.
Type:
Application
Filed:
March 28, 2011
Publication date:
August 8, 2013
Inventors:
Patricia Meillour, Chrystelle Le Danvic, Patrice Humblot, Philippe Chemineau, Christine Briant, Olivier Gerard
Abstract: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.
Type:
Grant
Filed:
October 12, 2011
Date of Patent:
August 6, 2013
Assignee:
Cerecor, Inc.
Inventors:
Blake Paterson, Mark Ginski, Brendan Canning
Abstract: Disclosed are a water-soluble metal-processing agent and a coolant both of which have excellent microbial deterioration resistance and are less likely to go rotten, a method for preparing the agent or the coolant, and a metal processing method. The water-soluble metal-processing agent or the coolant comprises an N,N,N?,N?-tetraalkyldiamine compound. The metal processing method is characterized by processing a metal of interest by using the water-soluble metal-processing agent or the coolant.
Abstract: Aqueous alkali metal glyphosate compositions are disclosed. The compositions comprise an aqueous concentrate of an alkali metal glyphosate, a surfactant blend comprising an etheramine component, and an optional water-miscible solvent. A mixture of the surfactant blend and solvent is gel-free and monophasic. Adjusting the pH of the aqueous concentrate to be within the range of 4.0 to 4.5 surprisingly enables preparation of a highly concentrated aqueous alkali metal glyphosate composition having good elevated temperature stability and a high cloud point. For instance, a 540 g.a.e./L formulation comprising the composition exhibits good stability at 54° C. Gel-free, monophasic surfactant blends useful in the glyphosate compositions are also disclosed.
Abstract: Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K+ channel openers and ?-lactam antibiotics are used to enhance glutamate transport and to treat depression-related mood disorders and depressive symptoms.
Abstract: The invention describes essentially a non-therapeutical process for deterring vermin, which is based on the usage of the largely known beta amino-alcohol derivatives of formula (I), as defined herein before. Furthermore, it describes the corresponding vermin-deterring compositions which contain these substances as the active ingredient, compounds of the formula (I) for the preparation of vermin-deterring compositions, and the use of compounds of formula (I) in the defense against vermin. Thus, the invention describes how and in which form the compounds of the formula (I) or their acid addition salts are used to deter vermin from materials, places or warm-blooded animals.
Type:
Grant
Filed:
November 21, 2007
Date of Patent:
December 25, 2012
Assignee:
Novartis AG
Inventors:
Pierre Ducray, Tania Cavaliero, Maike Lohrmann, Jacques Bouvier
Abstract: A composition and treatment method are disclosed for one or more of alpha, beta, and gamma-Cyclodextrin and a natural molecule or fragment thereof wherein the natural molecule is sometimes Glutathione, is non-acetylated, non-Esterified, and non-fatty acid attached, and the composition is administered parenterally and non-interveneously.
Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.
Abstract: An extraction method for extracts of Pelargonium citronellum with improved methylhexaneamine content is provided. The method involves separating the oil phase from the aqueous phase; concentrating the aqueous phase; purifying the oil phase; and recombining the resulting material. Additionally, extracts of Pelargonium citronellum prepared by the extraction method are provided. The extracts are useful in compositions, for example as dietary supplements, and for appetite suppression.
Type:
Application
Filed:
August 8, 2011
Publication date:
September 6, 2012
Inventors:
James Akrong, Shawn Shirazi, Jason Peters, John Doherty
Abstract: An extraction method for extracts of Geranium or Pelargonium with improved methylhexaneamine content is provided. The method involves separating the oil phase from the aqueous phase; concentrating the aqueous phase; purifying the oil phase; and recombining the resulting material. Additionally, extracts of Geranium or Pelargonium prepared by the extraction method are provided. The extracts are useful in compositions, for example as dietary supplements, and for appetite suppression.
Type:
Application
Filed:
March 2, 2011
Publication date:
September 6, 2012
Applicant:
Northern Innovations and Formulations Corp.
Inventors:
James Akrong, Shawn Shirazi, Vincent Scalisi, Jason Peters
Abstract: Described are methods of improving insulin sensitivity, and treating fatty liver disease (including non-alcoholic steatohepatitis (NASH)), by administering specific inhibitors of PKC delta.
Abstract: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrochloride, hydrobromide, hydroacetate or hydroanionic form.
Type:
Grant
Filed:
September 13, 2006
Date of Patent:
April 17, 2012
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Hector F. DeLuca, Katie Beth Williams, Katarzyna Barcyka
Abstract: Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K+ channel openers and ?-lactam antibiotics are used to enhance glutamate transport and to treat depression-related mood disorders and depressive symptoms.
Abstract: The present invention provides: a carbon nanohorn composite including a carbon nanohorn, a substance encapsulated in the carbon nanohorn, and a polyamine adsorbed by chemical reaction firmly to a surface functional group present on the opening part on the surface of the carbon nanohorn, wherein the release amount and release rate of the encapsulated substance can be controlled using the difference in size, substituent or three-dimensional structure of the polyamine, which is used as a plug; a method of controlling the release of the encapsulated substance; and a process for producing the carbon nanohorn composite. The release amount and release rate of the substance encapsulated in the carbon nanohorn composite is controlled by selecting a polyamine molecule, which plugs the opening part formed in the carbon nanohorn by oxidation, by its size, substituent or three-dimensional structure.
Abstract: A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.
Abstract: A composition for removing a radioactive element or compound such as systemic transuranic compounds, from mammals comprises a pharmaceutical carrier and a decorporation agent comprising ester and amide derivatives of DTPA. A method of treating a mammal to remove systemic compounds utilizing the DTPA derivatives is also disclosed.
Type:
Grant
Filed:
October 29, 2008
Date of Patent:
October 4, 2011
Assignee:
University of Kentucky Research Foundation
Abstract: There are provided compositions and methods to aggregate mucus using a plurality of positively charged nanoparticles. There are also provided compositions and methods for inducing contraception in the subject.
Abstract: The invention provides methods for treating and preventing a neurodegenerative disease associated with aberrant protein aggregation by modulating the expression and/or activity of XBP-1, IRE-1 alpha, and/or EDEM. The present invention also pertains to methods for identifying compounds that modulate the expression and/or activity of XBP-1, 1RE-1 alpha, and/or EDEM. The present invention further provides methods for determining whether a subject is at risk of developing or has developed a neurodegenerative disease associated with aberrant protein aggregation.
Type:
Application
Filed:
June 23, 2009
Publication date:
June 16, 2011
Applicant:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.
Abstract: Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine.
Abstract: A method for decreasing nicotine and other substance use in humans is disclosed. Iptakalim hydrochloride (IPT) is a novel nicotine acetylcholine receptor (nAChR) blocker. According to the disclosed method, IPT is used to block human ?4?2-nAChR function. Specifically, IPT exhibits a selective blockade of ?4 subunit-containing human nAChR subtypes. According to the disclosed method, IPT is thus used to block the major nicotine targets in the brain, the ?4?2-nAChRs natively expressed in midbrain (VTA) DA system, the brain reward center, and in turn to reduce the nicotine-induced reward signals, namely dopamine level increase in nucleus accumbens. Therefore, IPT is capable of servicing as a nAChR antagonist agent and thus is a novel treatment for decreasing nicotine dependence in humans.
Abstract: There is presented an alkaline disinfectant in the form of a multi-component composition, with each component being relatively benign until mixed with the other components in a ready-to-use solution. The invention further relates to the use of the composition in a variety of applications and apparatus for mixing and dispensing thereof. Furthermore, the invention relates to the use of components that synergistically provide effective biocidal activity in a broad spectrum of organisms, including germs, molds, viruses, bacteria, bacteria spores, or other microbes or pathogens. The composition provides a chemical system that kills all known plants, animals and microbes by raising pH and rapidly, but indirectly, transporting hydroxide into cells by use of ammonia compounds and/or amine compounds as neutral transporters. The composition components synergistically operate together to provide a disinfecting/cleaning composition useful for many different applications.
Abstract: The present disclosure generally relates to a multi-component biocide composition comprising a borate component in combination with an azole component to both inhibit mold fungi, decay fungi, such as brown-rot fungi and white-rot fungi, and to resist insect infestation.
Type:
Grant
Filed:
March 21, 2007
Date of Patent:
December 28, 2010
Assignee:
The United States of America as represented by the Secretary of Agriculture
Inventors:
Carol A. Clausen, Vina W. Yang, Michael H. West, Erlene West, legal representative
Abstract: Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.
Abstract: The invention provides a method for treating septic shock or endotoxemia, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising formula I, II, III or IV and their salt, ester or solvate thereof.
Abstract: Described herein are medical devices which are configured for implantation or insertion into a subject, preferably a mammalian subject. The medical devices contain one or more multilayer regions, which contain: (a) one or more (typically a plurality of) charged nanoparticle layers and (b) one or more (typically a plurality of) charged polyelectroyte layers. Such multilayers have a number of desirable attributes, including high strength, non-compliance, and flexibility. Also described herein are methods of making such devices.
Abstract: The subject invention provides materials and methods for improving alcohol metabolism in animals. In a preferred embodiment, the invention provides methods for increasing the ability of people to consume alcohol while reducing hangovers or other effects of intoxication. Specifically exemplified herein is the use of a cysteamine compound to reduce the adverse effects of alcohol consumption. For example, the undesirable and unpleasant symptoms association with hangovers can be reduced through consumption, according to the subject invention, of cysteamine hydrochloride.